Ovid Therapeutics
OVID
77 hedge funds and large institutions have $167M invested in Ovid Therapeutics in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 17 reducing their positions, and 3 closing their positions.
467% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 3
47% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 17
20% more funds holding
Funds holding: 64 → 77 (+13)
13.3% more ownership
Funds ownership: 59.98% → 73.28% (+13%)
3% more capital invested
Capital invested by funds: $163M → $167M (+$4.17M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$2.96M |
| 2 |
BlackRock
New York
|
+$2.73M |
| 3 |
FWM
FFT Wealth Management
Philadelphia,
Pennsylvania
|
+$1.35M |
| 4 |
Morgan Stanley
New York
|
+$768K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$343K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$444K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$155K |
| 3 |
Renaissance Technologies
New York
|
-$101K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$66.2K |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
-$60.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IGWM
76
ICA Group Wealth Management
Denver,
Colorado
| $177 | +$188 | +55 | New |
|
77
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $32 | +$34 | +10 | New |
|
|
JF
78
Jump Financial
Chicago,
Illinois
| – | -$60.7K | -15,811 | Closed |
|
79
Allspring Global Investments
Charlotte,
North Carolina
| – | -$24.2K | -6,294 | Closed |
|
80
Russell Investments Group
London,
United Kingdom
| – | -$219 | -57 | Closed |
|
OVID Hedge Fund Activity: Q4 2023 in Review
77 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2023, worth a combined $167M — up 2.6% from $163M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new OVID positions and 3 closed out — a net gain of 14 holders — while 25 added to existing stakes and 17 trimmed.
The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $2.96M. The largest seller was Rubric Capital Management (New York), cutting an estimated $444K.
- 77 institutional investors held Ovid Therapeutics (OVID) as of Q4 2023, up from 64 in Q3 2023.
- Funds reported $167M of Ovid Therapeutics stock for Q4 2023, up 2.6% quarter-over-quarter.
- 17 funds opened new Ovid Therapeutics positions in Q4 2023 and 3 closed out, a net change of +14 holders.
- The largest Ovid Therapeutics buyer in Q4 2023 was Blue Owl Capital Holdings, an estimated $2.96M added.
- The largest Ovid Therapeutics seller in Q4 2023 was Rubric Capital Management (New York), an estimated $444K sold.
Based on aggregated 13F filings for Q4 2023.